An expert discussion on the atypical hemolytic uremic syndrome nomenclature—identifying a road map to precision: a report of a National Kidney Foundation Working Group
The term atypical hemolytic uremic syndrome has been in use since the mid-1970s. It was initially used to describe the familial or sporadic form of hemolytic uremic syndrome as opposed to the epidemic, typical form of the disease. Over time, the atypical hemolytic uremic syndrome term has evolved into being used to refer to anything that is not Shiga toxin-associated hemolytic uremic syndrome. The term describes a heterogeneous group of diseases of disparate causes, a circumstance that makes defining disease-specific natural history and/or targeted treatment approaches challenging. A working group of specialty-specific experts in the thrombotic microangiopathies was convened to review the validity of this broad term in an era of swiftly advancing science and targeted therapeutics. A Delphi approach was used to define and interrogate some of the key issues related to the atypical hemolytic uremic syndrome nomenclature.
Authors
- Michelle M. O’Shaughnessy (ORCID: https://orcid.org/0000-0002-0406-1308)
- David L. Feldman (ORCID: https://orcid.org/0000-0003-2288-5017)
- Richard M. Burwick (ORCID: https://orcid.org/0000-0002-2340-3772)
- Richard J. Smith (ORCID: https://orcid.org/0000-0003-1201-6731)
- Nelson Leung (ORCID: https://orcid.org/0000-0002-5651-1411)
- C. John Sperati (ORCID: https://orcid.org/0000-0002-8409-0714)
- Giuseppe Remuzzi (ORCID: https://orcid.org/0000-0002-6194-3446)
- David Kavanagh (ORCID: https://orcid.org/0000-0003-4718-0072)
- Sangeeta Hingorani (ORCID: https://orcid.org/0000-0003-3743-1325)
- Carla Nester (ORCID: https://orcid.org/0000-0002-0629-7576)
- Samir V. Parikh (ORCID: https://orcid.org/0000-0001-7023-525X)
- Nicole C. A. J. van de Kar (ORCID: https://orcid.org/0000-0002-1990-1189)
- Shruti Chaturvedi (ORCID: https://orcid.org/0000-0001-6832-2389)
- Bradley P. Dixon (ORCID: https://orcid.org/0000-0003-3704-0922)
- Spero R. Cataland (ORCID: https://orcid.org/0000-0001-8977-6910)
- Marina Vivarelli (ORCID: https://orcid.org/0000-0002-2448-1959)
- Christoph P. B. Licht (ORCID: https://orcid.org/0000-0003-4168-3277)
- Anuja Java (ORCID: https://orcid.org/0000-0003-0433-238X)
- Meryl Waldman (ORCID: https://orcid.org/0000-0001-8698-0502)
- Fádi Fakhouri (ORCID: https://orcid.org/0000-0001-5390-8002)
- H. Terence Cook (ORCID: https://orcid.org/0000-0002-8950-1041)
- Marina Noris (ORCID: https://orcid.org/0000-0001-7651-5033)
- Flora Peyandi
- Adam Cuker
- Patrick D. Walker
Institutions
- Seattle Children's Hospital (US)
- National Institutes of Health (US)
- National Kidney Foundation (US)
- Mayo Clinic (US)
- Johns Hopkins University (US)
- Radboud University Nijmegen (NL)
- Imperial College Healthcare NHS Trust (GB)
- University of Milan (IT)
- Mario Negri Institute for Pharmacological Research (IT)
- University of Washington (US)
- Washington University in St. Louis (US)
- Johns Hopkins Medicine (US)
- Hospital for Sick Children (CA)
- Newcastle upon Tyne Hospitals NHS Foundation Trust (GB)
- Hammersmith Hospital (GB)
- University Hospital Galway (IE)
- Radboud University Medical Center (NL)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- Arkana Laboratories (US)
- National Institute of Diabetes and Digestive and Kidney Diseases (US)
- University of Iowa Stead Family Children’s Hospital (US)
- Pomona Valley Hospital Medical Center (US)
- Radboud Institute for Molecular Life Sciences (NL)
- Bambino Gesù Children's Hospital (IT)
- Mayo Clinic in Arizona (US)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Imperial College London (GB)
- The Ohio State University (US)
- University of Pennsylvania (US)
- Newcastle University (GB)
- The University of Texas Southwestern Medical Center (US)
- University of Colorado Denver (US)
- University of Lausanne (CH)
Publication Details
- Journal
- Kidney International
- Published
- 2024-08-20
- DOI
- https://doi.org/10.1016/j.kint.2024.05.021
- Citations
- 30
- Primary Topic
- Complement system in diseases
- Type
- article
- Field-Weighted Citation Impact
- 7.21
Funders
- Alexion Pharmaceuticals
- National Kidney Foundation
- Akershus Universitetssykehus